Pain Therapeutics (PTIE) Drops 8.77% on January 21

Equities Staff |

Pain Therapeutics (PTIE) was one of the Russell 2000's biggest losers for Thursday January 21 as the stock slid 8.77% to $1.56, a loss of $-0.15 per share. Starting at an opening price of $1.65 a share, the stock traded between $1.55 and $1.68 over the course of the trading day. Volume was 111,520 shares over 217 trades, against an average daily volume of 96,394 shares and a total float of 45.76 million.

The losses send Pain Therapeutics down to a market cap of $71.38 million. In the last year, Pain Therapeutics has traded between $3.65 and $1.53, and its 50-day SMA is currently $1.84 and 200-day SMA is $1.87.

Pain Therapeutics Inc is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma.

Pain Therapeutics is based out of Austin, TX and has some 9 employees. Its CEO is Remi Barbier.

For a complete fundamental analysis analysis of Pain Therapeutics, check out’s Stock Valuation Analysis report for PTIE. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Enertopia Corp

Enertopia Corp is engaged in the exploration of lithium in Nevada, USA. The Company's project includes Central Nevada Lithium Brine Projects.

Private Markets


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…